Evidence map›Paper›PMID 32394880›Full record

Trial reportThe American journal of tropical medicine and hygiene2020

Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial.

Anna P Durbin, Kristen K Pierce, Beth D Kirkpatrick, Palmtama Grier, Beulah P Sabundayo, Helen He, Michele Sausser, Amy Falk Russell, Jason Martin, Donna Hyatt and 6 more

Open access · bronzeAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of tropical medicine and hygiene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Dengue Vaccines.Current topics in microbiology and immunology · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Anna P Durbin1Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Kristen K Pierce2Department of Microbiology and Molecular Genetics, Vaccine Testing Center, Larner College of Medicine, University of Vermont, Burlington, Vermont.
Beth D Kirkpatrick2Department of Microbiology and Molecular Genetics, Vaccine Testing Center, Larner College of Medicine, University of Vermont, Burlington, Vermont.
Palmtama Grier1Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Beulah P Sabundayo1Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Helen He1Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Michele Sausser4Merck & Co., Inc., Kenilworth, New Jersey.
Amy Falk Russell4Merck & Co., Inc., Kenilworth, New Jersey.
Jason Martin4Merck & Co., Inc., Kenilworth, New Jersey.
Donna Hyatt4Merck & Co., Inc., Kenilworth, New Jersey.
Melissa Cook4Merck & Co., Inc., Kenilworth, New Jersey.
Jeffrey R Sachs4Merck & Co., Inc., Kenilworth, New Jersey.
Andrew Wen-Tseng Lee4Merck & Co., Inc., Kenilworth, New Jersey.
Liman Wang4Merck & Co., Inc., Kenilworth, New Jersey.
Beth-Ann Coller4Merck & Co., Inc., Kenilworth, New Jersey.
Stephen S Whitehead5Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USJohns Hopkins University · USUniversity of Vermont · USNational Institutes of Health · US

Funding

Clinical Trials of Biodefense Vaccines (Dengue, West Nile Virus, TBEV)ZIAAI000987 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WHITEHEAD, STEPHEN · 2009 to 2025
$37.9M
6 · The paper itself

Abstract

New dengue vaccines are needed to prevent this globally expanding vector-borne disease. The V180 vaccine candidate consists of four recombinant, soluble, dengue virus envelope glycoproteins and has been previously evaluated in two clinical trials for safety and immunogenicity in

Indexed as

Immunization, SecondaryAdjuvants, ImmunologicAdultAluminum HydroxideAntibodies, NeutralizingDengueDengue VaccinesDengue VirusDouble-Blind MethodFemaleHumansImmunogenicity, VaccineInjection Site ReactionMaleMiddle AgedNeutralization TestsAdjuvants, ImmunologicAluminum HydroxideAntibodies, NeutralizingDengue VaccinesVaccines, AttenuatedVaccines, SubunitVaccines, SyntheticViral Envelope Proteins

Identifiers

PMID32394880
PMCPMC7410446
OpenAlexW3025486761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.